CMS. CDN MSOLAR CORP

Blueberries Announces Call-in and Webcast Details for its Annual General and Special Meeting (“AGM”)

Blueberries Announces Call-in and Webcast Details for its Annual General and Special Meeting (“AGM”)

TORONTO, July 24, 2020 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce call-in numbers and webcast link for the Annual General and Special Meeting of the shareholders of Blueberries Medical Corp. (the “AGM”).  

The AGM will be held on Friday, July 31, 2020 at 1:00 pm Eastern Time at 82 Richmond Street East, Toronto, Ontario, Canada M5C 1P1.

In response to the ongoing global COVID-19 pandemic, the board of directors of Blueberries is advising shareholders not to attend the AGM in-person. After considering recent Provincial and Federal guidance regarding public gatherings and to proactively protect the health and well-being of Blueberries’ shareholders, employees, and service partners who participate in the AGM, the AGM will also be hosted in a virtual setting via webcast and teleconference.

In order to streamline the meeting process, the Company strongly encourages shareholders to vote in advance of the meeting using the Form of Proxy or Voting Instruction Form mailed to them with the meeting materials. Comprehensive information with respect to how registered and beneficial shareholders may vote in advance of the meeting is available in Blueberries’ Management Information Circular, also filed on SEDAR.

The deadline to vote your proxy in advance of the meeting is 1:00 pm, Eastern Time on Wednesday, July 29, 2020.

The webcast and teleconference will allow shareholders to listen to the proceedings and ask questions verbally through the teleconference. Details for shareholders interested in calling-in to the meeting are below. Participants should login and/or dial in approximately 10 minutes prior to the start time.

Date and Time:      Friday, July 31, 2020 at 1:00 PM Eastern Time
Shareholder Access:   
Call-in No.: 647-723-3984
Toll Free: 1-866-365-4406 (Canada/US)

018000125551 (Colombia)

Access Code: 3616167#

Webcast: Join Zoom Meeting

Meeting ID:      881 2934 8804
Passcode:  977183
Dial by your location:  Colombia

Colombia

Colombia

Colombia

Colombia

Canada

Canada

Canada

Canada

Canada

Canada
Find your local number: 

    

Following the formal proceedings of the AGM, management will provide a business update and presentation. All interested parties are invited to attend the AGM and participate in the management update.

About Blueberries Medical Corp.

Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.

Additional information about the Company is available at .

For more information, please contact:

Camilo Villalba, Chief Executive Officer



Tel: +57 (313) 483 0131

Ian Atacan, Chief Financial Officer



Tel: +1 (416) 562 3220

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: closing of the proposed transactions and achieving milestones in 2019 as contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

EN
24/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CDN MSOLAR CORP

 PRESS RELEASE

Blueberries Medical Announces C$1 Million Non-Brokered Private Placeme...

Blueberries Medical Announces C$1 Million Non-Brokered Private Placement TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares ("Common Shares") at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the "Offering"). The net proceeds from ...

 PRESS RELEASE

Blueberries Medical Announces C$1 Million Non-Brokered Private Placeme...

Blueberries Medical Announces C$1 Million Non-Brokered Private Placement TORONTO, March 07, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the “Offering”). The net proceeds from ...

 PRESS RELEASE

Blueberries Medical Announces Closing of C$2 Million Non-Brokered Priv...

Blueberries Medical Announces Closing of C$2 Million Non-Brokered Private Placement TORONTO, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, announces a non-brokered private placement consisting of the sale of 180,716,00 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1,987,876 (or approximately US$1,250,000) (the “Offering”). The net proceeds from the ...

 PRESS RELEASE

Blueberries Medical Announces C$2 Million Non-Brokered Private Placeme...

Blueberries Medical Announces C$2 Million Non-Brokered Private Placement TORONTO, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, announces a non-brokered private placement consisting of the sale of 180,716,000 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1,987,876 (or approximately US$1,250,000) (the “Offering”). The net proceeds from the sale of th...

 PRESS RELEASE

Blueberries Medical Reports Q1-2023

Blueberries Medical Reports Q1-2023 Financial Results, Expands Deals, Achieves Revenue Growth, Enhances Cost Efficiency, and Announces Board and Executive Updates TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) the Canadian parent of Blueberries S.A.S. (“BBSAS”), a leading player in the cannabis industry (together the “Company” or "Blueberries") is thrilled to announce its exceptional financial and business performance for the first quarter ended March 31, 2023. The company has demonstrated remarkable growth, doubling its revenue fr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch